EMOttawa Blog
  • Ottawa Handbook of Emergency Medicine
  • DEM Tri-Cycle Report
  • EMOttawa Podcast
  • Point-of-Care Echo
  • Grand Round Summaries
  • Journal Club
  • Commentary
  • Ultrasound
  • Infographics
  • EDI
  • Prehospital and Transport Medicine
  • Ottawa Acute Care Resources
  • About Us
Select Page
Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial

Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial

by Anchaleena Mandal, Christian Vaillancourt | Mar 5, 2026 | Featured

Methodology Score: 4.5/5 Usefulness Score: 4/5 Stiell IG, et al. BMJ. 2025 Nov 11;391:e085632. doi: 10.1136/bmj-2025-085632. Question and Methods: This is a multi-center, open-label, patient randomised trial comparing the effectiveness and safety of cardioversion with...
Electrical vs Chemical Cardioversion in ED patients with Atrial Fibrillation (RAFF2)

Electrical vs Chemical Cardioversion in ED patients with Atrial Fibrillation (RAFF2)

by Shahbaz Syed | Jan 31, 2020 | Cardiology, Featured, Infographics, Journal Club

RAFF2 Ian Stiell and colleagues are back at it with atrial fibrillation; The RAFF2 trial (Electrical versus Chemical cardioversion for Emergency Department patients with Atrial Fibrillation (RAFF2); A partial factorial randomized trial) was published in The Lancet...
  • Facebook
  • Twitter
  • Instagram
  • YouTube

Mission Statement

World-Class Emergency Medicine: To provide outstanding compassionate emergency care through practice-changing research and innovative medical education. For more about our department, visit us at EMOttawa.

Categories

Archives

Free Open Access Medical Education content by EMOttawa is under a Creative Commons Attribution-NonCommercial ShareAlike 4.0 International License.